ProSomnus says OAT therapy as effective as CPAP
By HME News Staff
Updated 10:12 AM CDT, Wed August 23, 2023
PLEASANTON, Calif. – Precision oral appliance therapy was effective among 90% of moderate and 85% of severe OSA patients during a recent study, says ProSomus, maker of the ProSomnus EVO. The company’s First Line Obstructive Sleep Apnea Treatment (FLOSAT) study looked at 136 patients to compare the effectiveness of precision OAT vs. CPAP therapy. Key findings to date include: Precision oral appliance therapy is effective, and non-inferior to CPAP, as a first-line treatment for moderate to severe OSA; and precision oral appliance therapy was preferred by patients, with 98% continuing therapy at three months versus 22% discontinuing CPAP therapy over the same period of time. “The FLOSAT study was designed to evaluate whether precision oral appliance therapy could be utilized for the very practical and emergent issue of patients with OSA who could not access CPAP due to the recall,” said Dr. Olivier Vanderveken, Antwerp University Hospital. “The preliminary results of this study indicate that precision oral appliances are an effective and patient preferred treatment option, which is particularly relevant for the growing number of sleep clinicians practicing the P4 approach to making medicine more predictive, preventive, personalized and participatory.”
Comments